Incretin-mimetic therapies and pancreatic disease: A review of observational data

Current Medical Research and Opinion

Volumn 30, Issue 12, 2014, Pages 2471-2481

  Suarez, Elizabeth A ^a   Koro, Carol E ^b   Christian, Jennifer B ^b   Spector, Alicia D ^a,c   Araujo, Andre B ^a,d   Abraham, Sybil ^b  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PatientsLikeMe   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Acute pancreatitis; Incretin therapies; Pancreatic cancer; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN;

ACUTE DISEASE; AGONISTS; DIABETES MELLITUS, TYPE 2; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PANCREATIC NEOPLASMS; PANCREATITIS;

ACUTE DISEASE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INCRETINS; OBSERVATIONAL STUDY AS TOPIC; PANCREATIC NEOPLASMS; PANCREATITIS; RECEPTORS, GLUCAGON;

EID: 84914094260     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.960515     Document Type: Review

References (54)

1. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med 2014;370:794-7
2. Meisterfeld R, Ehehalt F, Saegar HD, et al. Pancreatic disorders and diabetes mellitus. Exp Clinl Endocrinol Diabetes 2008;116(Suppl 1):S7-12
3. Eland IA, Sundstrom A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol 2006;41:1484-90
4. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
5. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metabol 2010;12:766-71
6. Gonzalez-Perez A, Schlienger RG, Garcia Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010;33:2580-5
7. Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-704
8. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8
9. Shen HN, Chang YH, Chen HF, et al. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med 2012;29:1419-24
10. Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PloS One 2012;7:e53224
11. Xue Y, Sheng Y, Dai H, et al. Risk of development of acute pancreatitis with pre-existing diabetes: a meta-analysis. Eur J Gastroenterol Hepatol 2012;24:1092-8
12. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8
13. Ansary-Moghaddam A, Huxley R, Barzi F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Canc Epidemiol Biomarkers Prev 2006;15:2435-40
14. Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Canc Epidemiol Biomarkers Prev 2009;18:2397-405
15. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003;27:143-9
16. Bosetti C, Rosato V, Polesel J, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Canc 2012;64:643-51
17. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metabol 2012;14:1123-8
18. Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Canc Causes Contr 2010;21:879-87
19. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007;102:2696-707
20. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010;15:548-55
21. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-7
22. Jamal MM, Yoon EJ, Vega KJ, et al. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 2009;15:5274-8
23. Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-71
24. Luo J, Iwasaki M, Inoue M, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan - the JPHC study. Canc Causes Contr 2007;18:603-12
25. Stevens RJ, Roddam AW, Spencer EA, et al. Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. Int J Canc 2009;124:2400-5
26. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Canc Epidemiol Biomarkers Prev 2006;15:1458-63
27. Batty GD, Shipley MJ, Marmot M, et al. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Canc Causes Contr 2004;15: 873-81
28. Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620-6
29. Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pacific J Canc Prev 2006;7:253-9
30. Rousseau MC, Parent ME, Pollak MN, et al. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Canc 2006;118:2105-9
31. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Canc 2011;47:1928-37
32. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA: a Cancer Journal for Clinicians 2010;60:207-21
33. Wells G, Shea B, O'Connell J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxfordasp [Last accessed 1 August 2013]
34. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica 2011;50:569-77
35. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
36. Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25
37. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
38. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metabol 2011;13:559-66
39. Dore DD, Hussein M, Hoffman C, et al. A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin 2013;29:1577-86
40. Funch D, Gydesen H, Tornoe K, et al. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metabol 2013;16:273-5
41. Li X, Zhang Z, Duke J. Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis. Pharmacoepidemiol Drug Saf 2013;23:234-9
42. Romley JA, Goldman DP, Solomon M, et al. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Therapeut 2012;14:904-11
43. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Internal Medicine 2013;173:534-9
44. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-18
45. Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis-diabetes- pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013;42:1227-37
46. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98:271-84
47. U.S. Food and Drug Administration. Information for Healthcare Professionals: Exenatide (marketed as Byetta). Update August 2008. Available at: http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm124713.htm [Last accessed 7 May 2014]
48. Moores K, Gilchrist B, Carnahan R, et al. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):194-202
49. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol 2013;16:48-56
50. Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012;5:29-41
51. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
52. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
53. Friedlin J, Overhage M, Al-Haddad MA, et al. Comparing methods for identifying pancreatic cancer patients using electronic data sources. AMIA Annual Symposium Proceedings 2010;2010:237-41
54. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94